jay2 22 33

JAY2-22-33, as a neuroprotective agent, can act by significantly reducing Aβ toxicity by delaying paralysis and improving cognitive performances in a transgenic mouse model of AD.

SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus inhibitor with an IC50 of 16.96 μM.

VEGFR-2-IN-33 (Compound 4d), a potent VEGFR inhibitor with an IC50 value of 61.04 nM, demonstrates significant inhibition of HepG2 cell proliferation with an IC50 of 4.31 nM, and is utilized for hepatocellular carcinoma (HCC) research [1].

VEGFR-2-IN-22 (Compound 25) is an inhibitor of VEGFR-2 and β-tubulin polymerization, with an IC50 of 19.82 nM for VEGFR-2, and is capable of inducing apoptosis.

COX-2-IN-22 is a COX-2 inhibitor (IC50: 8.6 μM) that can cross the blood-brain barrier and also exhibits inhibitory effects on AChE (IC50: 2.8 μM), BChE (IC50: 6.3 μM), β-Secretase (IC50: 15.3 μM), LOX-5 (IC50: 13.9 μM) and DPPH ( IC50: 6.8 μM) showed inhibitory effects.

SARS-CoV-2 Mpro-IN-22 (compound 4) is an effective inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 of 1.2 µg mL. This hydrolyzable tannin exhibits no significant cytotoxic activity in A549 and HUVEC cell lines.

SARS-CoV-2-IN-33 is an inhibitor of COVID-19. SARS-CoV-2-IN-3 exhibits good binding affinity (-8.0 Kcal/mole) for COVID-19 major protease (Mpro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 exhibits good anti-proliferative effects on cancer cells. SSARS-CoV-2-IN-33 can be used to study cancer and COVID-19.

COX-2-IN-33 (compound 5f) is a selective COX-2 inhibitor with an IC50 of 45.5 nM, demonstrating potential as an anti-inflammatory agent by effectively suppressing pro-inflammatory cytokine production in vivo while maintaining gastric safety [1].

GLP-2(1-33) (human) is an enteroendocrine hormone that stimulates intestinal epithelium growth.

intestinal epithelium-specific growth factor